Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

162
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
162
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

375
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
375
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

87
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
87
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

374
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
374
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

109
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
109
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

374
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
374

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Measuring patriotic emotional granularity: task-based validation, brief scale development, and cross-method evidence.

BMC psychology·2026
Same author

Should we screen for colorectal cancer with biennial FIT beginning at age 45 in Canada?

Journal of the Canadian Association of Gastroenterology·2026
Same author

MGDP: Mastering a Generalized Depth Perception Model for Quadruped Locomotion.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Saudi consensus statements on the management of irritable bowel syndrome.

Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association·2026
Same author

Future Global Outlook in Gastrointestinal and Liver Disorders: Consensus and Perspectives from the Leaders of Member Societies of the World Gastroenterology Organization.

Journal of gastrointestinal and liver diseases : JGLD·2026
Same author

Immunomodulatory effects of biodegradable Mg-Cu-Zn alloy in esophageal cancer.

Bioactive materials·2026

関連する実験動画

Updated: Jun 23, 2025

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

6.6K

胃潰瘍病

Majid A Almadi1, Yidan Lu2, Ali A Alali3

  • 1Division of Gastroenterology, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia; Division of Gastroenterology, The McGill University Health Center, Montréal General Hospital, McGill University, Montréal, QC, Canada.

Lancet (London, England)
|June 17, 2024
PubMed
まとめ
この要約は機械生成です。

胃潰瘍はしばしばH. pyloriまたは薬によって引き起こされ,酸抑制とH. pyloriの根絶によって管理されます. 適切なプロトンポンプ阻害剤 (PPI) の使用は重要であり,もはや指示されていない場合は処方停止を検討します.

さらに関連する動画

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

1.0K
Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

305

関連する実験動画

Last Updated: Jun 23, 2025

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

6.6K
Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

1.0K
Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

305

科学分野:

  • 胃腸内科
  • 内科 医学
  • 薬理学について

背景:

  • 胃潰瘍疾患 (PUD) は年間0. 12~1. 5%に発生する.
  • 一般的な原因はヘリコバクター・パイロリ感染症,NSAID/アスピリン使用,重篤な病気,または特異的要因です.
  • 管理には,H. pyloriの根絶,酸性抑制 (しばしばプロトンポンプ阻害剤 - PPI) と出血などの合併症の対処が含まれます.

研究 の 目的:

  • 胃潰瘍の現在の管理戦略をレビューする.
  • 抗血小板剤/抗血栓剤を服用している患者に対する特別な考慮事項について話し合う.
  • 進化する H. pylori 治療と予防のガイドラインを強調する.

主な方法:

  • PUD管理ガイドラインと研究に関する文献レビュー
  • H. pylori感染と酸性抑制に対する治療方法の分析
  • 予防の徴候と新たな治療法の検討

主要な成果:

  • H. pylori の治療の選択は,局所抗生物質耐性に依存する.
  • PPIは高リスクの患者に予防のために推奨されます.
  • カリウムの競争力のある酸阻害剤とH. pyloriワクチン接種は,将来の研究分野です.

結論:

  • 承認された用のために適切なPPIの使用は,一般的にリスクに優れている.
  • 指示が解決したときに,PPIの処方停止を考慮する必要があります.
  • ストレス潰瘍の出血管理と最適な患者/治療法の選択については,さらなる研究が必要である.